CERN09-02: Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults

January 01, 2015
Cancer - Brain
  1. Patient must be 18 years of age or older.
  2. Histologically proven intra-cranial or spinal ependymoma or anaplastic ependymoma. There must be pathologic or imaging confirmation of tumor progression or regrowth.

Please contact us for full eligibility criteria.

Tiffany Pearce